Q4 2025 Myriad Genetics Inc Earnings Call Transcript
Key Points
- Myriad Genetics Inc (MYGN) reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range.
- The company achieved strong test volume growth, with myRisk in oncology growing 14% and in the unaffected market growing 11% year-over-year.
- GeneSight volume grew 9% year-over-year, showing continued acceleration from the first half of 2025.
- The company reported a strong adjusted gross margin of 70% and healthy adjusted EBITDA of $14.3 million.
- Myriad Genetics Inc (MYGN) is on track to launch several new products in 2026, including AI-enhanced Prolaris and the FirstGene prenatal screen, which are expected to drive future growth.
- The company faced a headwind from UnitedHealthcare's decision on GeneSight, impacting average revenue per test.
- Fourth quarter Prolaris volume declined year-over-year due to Q2 order management disruptions.
- Prenatal volume growth faced challenges, with a modest pullback in the fourth quarter and expected year-over-year decline in the first quarter of 2026.
- The company anticipates a modest headwind in average selling price (ASP) across the portfolio in 2026.
- There is no expected revenue contribution from MRD tests in the 2026 revenue guidance, as coverage is anticipated in 2027.
Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter and full year 2025 earnings call. (Operator instructions.) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Matt Scalo, Senior Vice President of Investor Relations. Please go ahead.
Good afternoon, and welcome to Myriad Genetics fourth quarter and full year 2025 earnings call. During the call, we will review the financial results we released today, and afterwards, we will host a Q&A session. Our earnings release was issued this afternoon on Form 8âK and can be found on our website at investor.myriad.com.
I am Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer; Ben Wheeler, our Chief Financial Officer; and Mark Verratti, our Chief Operating Officer. Also joining us for Q&A will be Brian Donnelly, our Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
